Aileron Therapeutics, INC 8-K filings

Rein Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved an increase in authorized common stock and ratified auditor appointment.

Rein Therapeutics announced the pricing of a $50 million underwritten public offering of common stock, with net proceeds expected to fund its Phase 2 clinical trial for LTI-03.

Rein Therapeutics, Inc. announced the immediate resignation of Dr. Manuel C. Alves Aivado from its Board of Directors, citing no disagreements with company operations.

Rein Therapeutics, Inc. has secured a $2.5 million unsecured promissory note from Funicular Funds, LP, with a 20% original issue discount and a maturity date by June 30, 2026, or earlier upon a significant future capital raise.

Rein Therapeutics, Inc. has terminated its Pre-Paid Advance Agreement and Standby Equity Purchase Agreement with Yorkville, having drawn $3 million under the PPA with no penalties.

Rein Therapeutics announced FDA clearance to resume its U.S. Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis, with enrollment expected to restart in late 2025 or early 2026.

Rein Therapeutics, Inc. announced it received a third $1.0 million pre-paid advance from Yorkville, bringing total advances to $3.0 million under their $6.0 million agreement.

Rein Therapeutics received European Medicines Agency authorization to initiate its Phase 2 RENEW clinical trial for LTI-03 in idiopathic pulmonary fibrosis at sites in Germany and Poland.

Rein Therapeutics received encouraging preliminary FDA feedback, outlining a path to resolve the clinical hold on its LTI-03 Phase 2 RENEW trial for idiopathic pulmonary fibrosis.

Rein Therapeutics, Inc. announced it received a second $1.0 million pre-paid advance from Yorkville, bringing total advances to $2.0 million under their existing agreement.

Rein Therapeutics received UK regulatory approval to begin its Phase 2 clinical trial for LTI-03, a lead drug candidate for idiopathic pulmonary fibrosis.

Rein Therapeutics, Inc. has entered into two significant financing agreements with Yorkville, potentially raising up to $21 million through discounted equity sales and pre-paid advances, signaling a reliance on highly dilutive capital.

Rein Therapeutics, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where William C. Fairey was elected as a Class II director and named executive officer compensation was approved on an advisory basis.

Rein Therapeutics, Inc. announced a formal clinical hold by the FDA on its lead idiopathic pulmonary fibrosis (IPF) product candidate, LTI-03, pausing its Phase 2 RENEW trial, while also amending its corporate bylaws to lower the stockholder meeting quorum to 40%.

Rein Therapeutics, Inc. announced the adjournment of its 2025 Annual Meeting of Stockholders until July 23, 2025, as a quorum was not achieved, aiming to provide more time for shareholder participation.

Rein Therapeutics, Inc. announced a pause in U.S. enrollment and patient dosing for its Phase 2 RENEW trial of LTI-03 due to a clinical hold placed by the FDA, while the trial continues in other regions.

Rein Therapeutics reported its Q1 2025 financial results, initiated a Phase 2 trial for LTI-03 in IPF, and highlighted clinical and corporate advancements.

Rein Therapeutics announces agreements with warrant holders and Bios Equity Partners to raise approximately $5.05 million through warrant exercises, exchanges, and a private placement.

Rein Therapeutics replaces Marcum LLP with CBIZ CPAs as its independent registered public accounting firm, effective immediately on April 16, 2025.

Aileron Therapeutics, Inc. officially changes its name to Rein Therapeutics, Inc., with the new trading symbol 'RNTX' expected to commence on January 13, 2025.

Aileron Therapeutics reported positive results from a Phase 1b clinical trial for LTI-03 in IPF patients and announced its third quarter 2024 financial results.

Aileron Therapeutics held its 2024 Annual Meeting of Stockholders, electing two Class I directors and ratifying its independent auditor.

Aileron Therapeutics reported positive data from a Phase 1b clinical trial of LTI-03 for idiopathic pulmonary fibrosis and announced its second quarter 2024 financial results.

Aileron Therapeutics has entered into a new equity distribution agreement for up to $50 million in common stock and terminated a previous agreement.

Aileron Therapeutics has announced its 2024 annual meeting date and set deadlines for shareholder proposals and director nominations.

Aileron Therapeutics has appointed Timothy M. Cunningham as interim chief financial officer, effective May 16, 2024, following the departure of Charles Garner.

Aileron Therapeutics reported positive initial data from its LTI-03 clinical trial for idiopathic pulmonary fibrosis and its first quarter 2024 financial results.

Aileron Therapeutics has announced the pricing of a registered direct offering of common stock and warrants, aiming to raise approximately $20 million initially, with the potential for an additional $20 million from warrant exercises.

Aileron Therapeutics reported positive initial data from the first cohort of its Phase 1b clinical trial of LTI-03, showing statistically significant reductions in key biomarkers associated with fibrosis in patients with idiopathic pulmonary fibrosis.

Aileron Therapeutics announced its full year 2023 financial results, highlighted by a merger with Lung Therapeutics and progress in its clinical pipeline, with topline results for LTI-03 expected in Q3 2024.